The DOI matches its Crossref record; 173 of the 176 references it cites were found in a registry or an index.
Parkinson’s disease: genetics and pathogenesis
Abstract
Recent investigation into the mechanisms of Parkinson's disease (PD) has generated remarkable insight while simultaneously challenging traditional conceptual frameworks. Although the disease remains defined clinically by its cardinal motor manifestations and pathologically by midbrain dopaminergic cell loss in association with Lewy bodies, it is now recognized that PD has substantially more widespread impact, causing a host of nonmotor symptoms and associated pathology in multiple regions throughout the nervous system. Further, the discovery and validation of PD-susceptibility genes contradict the historical view that environmental factors predominate, and blur distinctions between familial and sporadic disease. Genetic advances have also promoted the development of improved animal models, highlighted responsible molecular pathways, and revealed mechanistic overlap with other neurodegenerative disorders. In this review, we synthesize emerging lessons on PD pathogenesis from clinical, pathological, and genetic studies toward a unified concept of the disorder that may accelerate the design and testing of the next generation of PD therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recessively inherited loss-of-function mutations in PTEN-induced kinase 1 (PINK1) and the E3 ubiquitin ligase PRKN are the most common genetic causes for early-onset PD, which occurs in about 5%–10% of cases [1, 2].”
From miRNA family miR-29 inhibits PINK1-PRKN signaling via ATG9A (2026) · cites this paper as [1]
In the citing paper
“Loss-of-function mutations in the genes encoding PINK1 and PRKN result in early-onset Parkinson disease (EOPD).”
From miRNA family miR-29 inhibits PINK1-PRKN signaling via ATG9A (2026) · cites this paper as [1]
In the citing paper
“A complex interplay of genetic and environmental factors is thought to drive the pathogenesis of PD, eventually leading to mitochondrial and autophagic dysfunction (Shulman et al., 2011).”
From Microbiome–microglia connections via the gut–brain axis (2019) · cites this paper as Shulman et al., 2011
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Research works printed but not linked: 4
- Parkinson J, 1817, An Essay on the Shaking Palsy
- Priyadarshi A, 2000, Neurotoxicology, 21, 435
- Gilks W, 2005, Lancet, 365, 415
- Nichols WC, 2005, Lancet, 365, 410
Cited by
Sorted by citations
Items 201–300 of 803
Tau Reduction Does Not Prevent Motor Deficits in Two Mouse Models of Parkinson's Disease
Morris, M., Koyama, A., Masliah, E., & Mucke, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029257 · Cited by 56
Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
Ganguly, U., Chakrabarti, S. S., Kaur, U., Mukherjee, A., & Chakrabarti, S. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666171129100944 · Cited by 58
Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics
Bardai, F. H., Ordonez, D. G., Bailey, R. M., Hamm, M. J., Lewis, J. M., & Feany, M. Β. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2006265 · Cited by 55
Self-citationŌmura, S., & Crump, A. (2019) · The Journal of Antibiotics · doi:10.1038/s41429-019-0141-8 · Cited by 56
Sheng, L., Stewart, T., Yang, D., Thorland, E., Soltys, D., Aro, P., Khrisat, T., Xie, Z., Li, N., Liu, Z., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00983-w · Cited by 56
Li, G., Zhang, Z., Quan, Q., Jiang, R., Szeto, S. S. W., Yuan, S., Wong, W., Lam, H. C., Lee, S. M., & Chu, I. K. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00152 · Cited by 57
Choi, J. H., Jang, M., Oh, S., Nah, S.-Y., & Cho, I. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00515 · Cited by 55
Zhu, X., Zhong, Y., Ge, Y., Ke-huan, L., & Lu, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-30436-3 · Cited by 55
Liu, Z., Chan, R., Cai, Z., Liu, X., Wu, Y., Yu, Z., Feng, T., Yang, Y., & Zhang, J. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02413-1 · Cited by 55
Khan, A. N., & Khan, R. H. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.031 · Cited by 58
Annonamine, a New Aporphine Alkaloid from the Leaves of Annona muricata
Matsushige, A., Kotake, Y., Matsunami, K., Otsuka, H., Ohta, S., & Takeda, Y. (2012) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.60.257 · Cited by 54
Miñones-Moyano, E., Friedländer, M. R., Pallarès-Albanell, J., Kagerbauer, B., Porta, S., Escaramís, G., Ferrer, I., Estivill, X., & Martí, E. (2013) · RNA Biology · doi:10.4161/rna.24813 · Cited by 56
Fractional anisotropy in the substantia nigra in Parkinson's disease: a complex picture
Lenfeldt, N., Larsson, A., Nyberg, L. H., Birgander, R., & Forsgren, L. (2015) · European Journal of Neurology · doi:10.1111/ene.12760 · Cited by 54
Ghanbari, M., Darweesh, S. K. L., de Looper, H. W. J., van Luijn, M. M., Albert Hofman, D., Ikram, M. A., Franco, O. H., Erkeland, S. J., & Dehghan, A. (2015) · Human Mutation · doi:10.1002/humu.22943 · Cited by 54
Revisiting the flip side: Long-term depression of synaptic efficacy in the hippocampus
Pinar, C., Fontaine, C. J., Triviño-Paredes, J., Lottenberg, C. P., Gil‐Mohapel, J., & Christie, B. R. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.06.001 · Cited by 60
Dietary Restriction and Neuroinflammation: A Potential Mechanistic Link
Bok, E., Jo, M., Lee, S., Lee, B.-R., Kim, J., & Kim, H.-J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030464 · Cited by 53
“PD is characterized by selective loss of dopaminergic neurons in the substantia nigra region [131].”
BackgroundInflammatory Mediators as Biomarkers in Brain Disorders
Nuzzo, D., Picone, P., Caruana, L., Vasto, S., Barera, A., Caruso, C., & Carlo, M. D. (2013) · Inflammation · doi:10.1007/s10753-013-9780-2 · Cited by 56
Anti-Parkinson activity of bioactive substances extracted from Holothuria leucospilota
Malaiwong, N., Chalorak, P., Jattujan, P., Manohong, P., Niamnont, N., Suphamungmee, W., Sobhon, P., & Meemon, K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.063 · Cited by 56
McKeon, J. E., Di, S., Li, L., & Chin, L. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1781-2 · Cited by 56
Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases
Katsuno, M., Tanaka, F., & Sobue, G. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301307 · Cited by 52
(PPR), E. P. O. P. P. P. A. T. R., Ockleford, C., Adriaanse, P., Berny, P. J., Brock, T. C. M., Duquesne, S., Grilli, S., Hernández, A. F., Bennekou, S. H., Klein, M., et al. (2017) · EFSA Journal · doi:10.2903/j.efsa.2017.4691 · Cited by 51
Song, J., Liu, L., Li, Z., Mao, T., Zhang, J., Zhou, L., Chen, X., Shang, Y., Sun, T., Luo, Y., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02621-9 · Cited by 51
Modulation of alpha-synuclein toxicity in yeast using a novel microfluidic-based gradient generator
Fernandes, J. T. S., Tenreiro, S., Gameiro, A., Chu, V., Outeiro, T. F., & Conde, J. P. (2014) · Lab on a Chip · doi:10.1039/c4lc00756e · Cited by 52
Joshi, A. U., Kornfeld, O. S., & Mochly‐Rosen, D. (2016) · Cell Calcium · doi:10.1016/j.ceca.2016.04.010 · Cited by 55
The role of LRRK2 in cell signalling
Harvey, K., & Outeiro, T. F. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180464 · Cited by 51
Coordination of Copper to the Membrane-Bound Form of α-Synuclein
Dudzik, C. G., Walter, É., Abrams, B. S., Jurica, M. S., & Millhauser, G. L. (2012) · Biochemistry · doi:10.1021/bi301475q · Cited by 50
A practical review of gastrointestinal manifestations in Parkinson's disease
Su, A., Gandhy, R., Barlow, C., & Triadafilopoulos, G. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.02.029 · Cited by 51
Mitochondrial alterations in Parkinson's disease human samples and cellular models
Zilocchi, M., Finzi, G., Lualdi, M., Sessa, F., Fasano, M., & Alberio, T. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.04.013 · Cited by 50
Proteomic analysis of protein homeostasis and aggregation
Laskowska, E., Kuczyńska‐Wiśnik, D., & Lipińska, B. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.12.003 · Cited by 49
Özen, Í., Ruscher, K., Nilsson, R. F., Flygt, J., Clausen, F., & Marklund, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020387 · Cited by 52
Liu, W., Lim, K., & Tan, E. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00318-w · Cited by 47
Diffusion tensor imaging and correlations to Parkinson rating scales
Lenfeldt, N., Hansson, W., Larsson, A., Nyberg, L. H., Birgander, R., & Forsgren, L. (2013) · Journal of Neurology · doi:10.1007/s00415-013-7080-2 · Cited by 49
Badrkhahan, S. Z., Sikaroodi, H., Sharifi, F., Kouti, L., & Noroozıan, M. (2019) · Applied Neuropsychology Adult · doi:10.1080/23279095.2019.1565762 · Cited by 49
The potential therapy with dental tissue-derived mesenchymal stem cells in Parkinson’s disease
Xiao, Z., Lei, T., Liu, Y., Yang, Y., Bi, W., & Du, H. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01957-4 · Cited by 49
Li, S., Ritz, B. R., Gong, Y., Cockburn, M., Folle, A. D., Rosario, I. D., Yu, Y., Zhang, K., Castro, E., Keener, A. M., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.160851 · Cited by 48
Sen, T., & Thummer, R. P. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00564-w · Cited by 52
Naringenin: its chemistry and roles in neuroprotection
Atoki, A. V., Aja, P. M., Shinkafi, T. S., Ondari, E. N., & Awuchi, C. G. (2023) · Nutritional Neuroscience · doi:10.1080/1028415x.2023.2243089 · Cited by 47
Athar, M., Lone, M. Y., Khedkar, V. M., & Jha, P. C. (2015) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2015.1077343 · Cited by 46
A novel and functional variant within the ATG5 gene promoter in sporadic Parkinson's disease
Chen, D., Zhu, C., Wang, X., Feng, X., Pang, S., Huang, W., Hawley, R. G., & Yan, B. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.01.044 · Cited by 48
Iakovakis, D., Hadjidimitriou, S., Charisis, V. S., Bostantjopoulou, S., Katsarou, Z., Klingelhoefer, L., Reichmann, H., Dias, S. B., Diniz, J. A., Trivedi, D., et al. (2018) · Frontiers in ICT · doi:10.3389/fict.2018.00028 · Cited by 47
Genetic analysis of SIRT1 gene promoter in sporadic Parkinson’s disease
Zhang, A., Wang, H., Qin, X., Pang, S., & Yan, B. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.059 · Cited by 45
Refolding of helical soluble α‐synuclein through transient interaction with lipid interfaces
Rovere, M., Sanderson, J. B., Fonseca‐Ornelas, L., Patel, D. S., & Bartels, T. (2018) · FEBS Letters · doi:10.1002/1873-3468.13047 · Cited by 46
Okarmus, J., Havelund, J. F., Ryding, M., Schmidt, S. I., Bogetofte, H., Heon‐Roberts, R., Wade‐Martins, R., Cowley, S. A., Ryan, B. J., Færgeman, N. J., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.04.022 · Cited by 46
Linking chronic kidney disease and Parkinson’s disease: a literature review
Meléndez-Flores, J. D., & Estrada-Bellmann, I. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-020-00623-1 · Cited by 44
Ariesandi, W., Chang, C., Chen, T.-E., & Chen, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053487 · Cited by 44
Drolet, R. E., Sanders, J. M., & Kern, J. T. (2011) · Journal of Neurogenetics · doi:10.3109/01677063.2011.627072 · Cited by 46
Shamsuzzama, S., Kumar, L., & Nazir, A. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00328 · Cited by 44
Schlaudraff, F., Gründemann, J., Fauler, M., Dragicevic, E., Hardy, J., & Liss, B. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.016 · Cited by 44
Pariyar, R., Bastola, T., Lee, D. H., & Seo, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042388 · Cited by 45
Circadian clock disruption promotes the degeneration of dopaminergic neurons in male Drosophila
Dorcikova, M. M., Duret, L. C., Pottié, E., & Nagoshi, E. (2023) · Nature Communications · doi:10.1038/s41467-023-41540-y · Cited by 42
Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease
Alberio, T., Pippione, A. C., Zibetti, M., Olgiati, S., Cecconi, D., Comi, C., Lopiano, L., & Fasano, M. (2012) · Scientific Reports · doi:10.1038/srep00953 · Cited by 44
Bose, A., & Beal, M. F. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14264 · Cited by 43
Jiang, X., Jin, T., Zhang, H., Miao, J., Zhao, X., Su, Y., & Zhang, Y. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/4578462 · Cited by 43
Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges
Kett, L. R., & Dauer, W. T. (2016) · Movement Disorders · doi:10.1002/mds.26797 · Cited by 43
Jacquet, A. D. R., Timmers, M. A., Ma, S. Y., Thieme, A., McCabe, G. P., Vest, J. H. C., Lila, M. A., & Rochet, J. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.02.021 · Cited by 41
E46K-like α-synuclein mutants increase lipid interactions and disrupt membrane selectivity
Rovere, M., Powers, A. E., Jiang, H., Pitino, J. C., Fonseca‐Ornelas, L., Patel, D. S., Achille, A., Langen, R., Varkey, J., & Bartels, T. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006551 · Cited by 42
Dopaminergic therapies modulate the T‐CELL proteome of patients with Parkinson's disease
Alberio, T., Pippione, A. C., Comi, C., Olgiati, S., Cecconi, D., Zibetti, M., Lopiano, L., & Fasano, M. (2012) · IUBMB Life · doi:10.1002/iub.1073 · Cited by 42
Biomarkers of Parkinson's disease and Dementia with Lewy bodies
Henchcliffe, C., Dodel, R. C., & Beal, M. F. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.002 · Cited by 42
Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications
Azevedo, R., Jacquemin, C., Villain, N., Fenaille, F., Lamari, F., & Bécher, F. (2022) · Cells · doi:10.3390/cells11081279 · Cited by 45
Xie, W., Gao, J., Jiang, R., Liu, X., Lai, F., Tang, Y., Xiao, H., Jia, Y., & Bai, Q. (2020) · NeuroToxicology · doi:10.1016/j.neuro.2019.11.009 · Cited by 40
Bonifácio, M. J., Sutcliffe, J. S., Torrao, L. R. D. S., Wright, L. C., & Soares-da-Silva, P. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.10.014 · Cited by 40
RGS6 as a Novel Therapeutic Target in CNS Diseases and Cancer
Ahlers‐Dannen, K. E., Chakravarti, B., & Fisher, R. A. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9899-9 · Cited by 40
Sirtuins as modifiers of Parkinson's disease pathology
Tang, B. L. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23806 · Cited by 41
Liu, Y., Geng, L., Zhang, J., Wang, J., Zhang, Q., Duan, D., & Zhang, Q. (2018) · Marine Drugs · doi:10.3390/md16030082 · Cited by 40
Neuroprotective gain of Apelin/APJ system
Zhou, J.-X., Shuai, N., Wang, B., Jin, X., Kuang, X., & Tian, S. (2021) · Neuropeptides · doi:10.1016/j.npep.2021.102131 · Cited by 40
Design and Customization of Telemedicine Systems
Martínez-Alcalá, C. I., Muñoz, M., & Fierro, J. M. M. (2013) · Computational and Mathematical Methods in Medicine · doi:10.1155/2013/618025 · Cited by 42
A Review of the Association Between Parkinson Disease and Malignant Melanoma
Disse, M., Reich, H., Lee, P. K., & Schram, S. S. (2016) · Dermatologic Surgery · doi:10.1097/dss.0000000000000591 · Cited by 40
Dopaminergic imaging in degenerative parkinsonisms, an established clinical diagnostic tool
Nicastro, N., Nencha, U., Burkhard, P. R., & Garibotto, V. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15561 · Cited by 41
Alberio, T., Bondi, H., Colombo, F., Alloggio, I., Pieroni, L., Urbani, A., & Fasano, M. (2014) · Molecular BioSystems · doi:10.1039/c3mb70611g · Cited by 39
LRRK2 mutations and neurotoxicant susceptibility
Lee, J.-W., & Cannon, J. R. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215579162 · Cited by 42
Mechanistic contributions of FBXO7 to Parkinson disease
Joseph, S., Schulz, J. B., & Stegmüller, J. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14253 · Cited by 39
Dong, X., Qiao, Q., Qian, Z., & Wei, G. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.03.006 · Cited by 39
Long Non-coding RNAs in Parkinson’s Disease
Xin, C., & Liu, J. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03230-3 · Cited by 39
Venkatesan, M., Nataraj, J., Karthik, R., Manivasagam, T., Ramachandran, S., Thenmozhi, A. J., Essa, M. M., & Guillemin, G. J. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9978-z · Cited by 38
Domenico, F. D., & Lanzillotta, C. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.05.008 · Cited by 38
A Conserved Role for p48 Homologs in Protecting Dopaminergic Neurons from Oxidative Stress
Dib, P. B., Gnägi, B., Daly, F., Sabado, V., Tas, D., Glauser, D. A., Meister, P., & Nagoshi, E. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004718 · Cited by 37
Pantano, L., Friedländer, M. R., Escaramís, G., Lizano, E., Pallarès-Albanell, J., Ferrer, I., Estivill, X., & Martı́, E. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv632 · Cited by 36
Understanding taurine CNS activity using alternative zebrafish models
Mezzomo, N. J., Fontana, B. D., Kalueff, A. V., Barcellos, L. J. G., & Rosemberg, D. B. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.008 · Cited by 37
Maqoud, F., Scala, R., Hoxha, M., Zappacosta, B., & Tricarico, D. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210119095626 · Cited by 39
Ma, S., Yu, J., Fu, J., Pan, L., Yu, H., Han, P., Zhang, Z., Peng, R., Xu, H., & Wang, Y. (2021) · Molecules · doi:10.3390/molecules26051377 · Cited by 37
Jacquet, A. D. R., Subedi, R., Ghimire, S. K., & Rochet, J. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.02.016 · Cited by 37
Lim, Y., Kehm, V. M., Li, C., Trojanowski, J. Q., & Lee, V. M. ‐. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.10.005 · Cited by 36
Flies with Parkinson's disease
Vanhauwaert, R., & Verstreken, P. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.02.020 · Cited by 37
Chauhan, A. K., & Mallick, B. N. (2019) · Sleep Medicine · doi:10.1016/j.sleep.2019.04.019 · Cited by 36
Role of the mtDNA Mutations and Mitophagy in Inflammaging
Dabravolski, S. A., Nikiforov, N. G., Zhuravlev, A. D., Orekhov, N. A., Grechko, A. V., & Orekhov, A. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031323 · Cited by 39
Wang, S., & Qi, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.916653 · Cited by 39
Patient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery
Tang, S., Xie, M., Cao, N., & Ding, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00789 · Cited by 37
Li, M., Xu, H., Chen, G., Sun, S., Wang, Q., Liu, B., Wu, X., Zhou, L., Chai, Z., Sun, X., et al. (2019) · Brain · doi:10.1093/brain/awz243 · Cited by 35
Ongoing Research on the Role of Gintonin in the Management of Neurodegenerative Disorders
Ikram, M. A., Ullah, R., Khan, A., & Kim, M. O. (2020) · Cells · doi:10.3390/cells9061464 · Cited by 36
Hong, Z., Tian, C., Stewart, T., Aro, P., Soltys, D., Bercow, M., Sheng, L., Borden, K., Khrisat, T., Pan, C., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011853 · Cited by 36
Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease
Nwabufo, C. K., & Aigbogun, O. P. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11267-9 · Cited by 37
Genetic analysis of the LAMP-2 gene promoter in patients with sporadic Parkinson's disease
Pang, S., Chen, D., Zhang, A., Qin, X., & Yan, B. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.07.044 · Cited by 36
Intrabodies as Neuroprotective Therapeutics
Messer, A. C., & Joshi, S. N. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0193-6 · Cited by 35
Collins, L., Adriaanse, L. J., Theratile, S. D., Hegarty, S. V., Sullivan, A. M., & O’Keeffe, G. W. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8820-8 · Cited by 35
Cressatti, M., Song, W., Turk, A. Z., Garabed, L. R., Benchaya, J. A., Galindez, C., Liberman, A., & Schipper, H. M. (2019) · Glia · doi:10.1002/glia.23645 · Cited by 35
Wang, H., Dou, S., Zhu, J., Shao, Z., Wang, C., & Cheng, B. (2020) · Brain Research · doi:10.1016/j.brainres.2020.147023 · Cited by 33
Bastioli, G., Piccirillo, S., Graciotti, L., Carone, M., Sprega, G., Taoussi, O., Preziuso, A., & Castaldo, P. (2024) · Cells · doi:10.3390/cells13151301 · Cited by 38
Shahidani, S., Rajaei, Z., & Alaei, H. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-018-0379-z · Cited by 33
Peshattiwar, V., Muke, S., Kaikini, A. A., Bagle, S., Dighe, V. D., & Sathaye, S. S. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.03.003 · Cited by 35
Novel Approaches Used to Examine and Control Neurogenesis in Parkinson′s Disease
Salmina, A. B., Рафаилевна, К. М., Vetchinova, A. S., & Illarioshkin, S. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179608 · Cited by 38
Metadata
- Authors
- Shulman, J. M., De Jager, P. L., & Feany, M. B.
- Affiliations
- Broad Institute (US)
- Departments of Neurology, Boston, Massachusetts 02115;
- Departments of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115;
- ORCID
- Shulman, Joshua M.
- Venue
- Annual Review of Pathology: Mechanisms of Disease
- Publisher
- Annual Reviews
- Published
- 2011-02-28
- Volume
- 6
- Issue
- 1
- Pages
- 193-222
- ISSN
- 1553-4006 (ISSN-L)
- 1553-4014
- OpenAlex
- W2129917779
- Cited by
- 801
- References
- 176
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 42 · 2023: 34 · 2022: 64 · 2021: 64 · 2020: 46 · 2019: 59 · 2018: 54 · 2017: 59 · 2016: 74 · 2015: 64 · 2014: 56 · 2013: 65 · 2012: 52
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annual Review of Pathology Mechanisms of Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, susceptibility genes, pathogenesis, dopaminergic neuron loss, Lewy bodies, non-motor symptoms, animal models, neurodegeneration, molecular pathways
- MeSH terms
- Animals, Humans, Parkinson Disease, Lewy Bodies, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
